Evaluation of Anti-Colorectal Cancer Activity in Methanolic Extract of Coleus forskohlii Root

Abstract

In a multistage process that involves moving from a precancerous lesion to a malignant tumour state, cancer develops when normal cells undergo the change into tumour cells. Colon cancer, also known as colorectal cancer (CRC), is the third most common and second-deadliest malignant tumour in the world. The current study's objective was to assess the anticancer potential of a methanolic extract of Coleus forskohlii root on the cancer cell line HT-29 using the MTT assay. A variety of assay methods were used, including morphological investigations, cell growth inhibition, and cell viability. At various concentrations (12.5, 25, 50, 100, and 200 µg/ml), the Coleus forskohlii extract was tested against the HT-29 cell line for its ability to inhibit cell proliferation. This study revealed that when concentrations rise the cell growth inhibition levels rise. The conventional medicine Doxorubicin had a growth inhibition of 72.70% at a dose of 5 µg/ml while the lowest growth inhibition was determined to be 9.55% at 12.5 µg/ml and the highest growth inhibition was 71.16% at 200 µg/ml. IC50 was greater than 123.90 µg/ml. According to the study's findings, a human colon adenocarcinoma cell line could be resistant to the anti-colorectal cancer effects of Coleus forskohlii root methanolic extract (HT-29).